Synergistic Anticancer Effects of Triptolide with Celastrol, Two Main Compounds from Thunder God Vin

来源 :2014医学科学前沿暨第三届个体化治疗与抗肿瘤药物研究新趋向研讨会 | 被引量 : 0次 | 上传用户:zxebabi
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Triptolide and celastrol are two most widely studied and promising compounds isolated from Thunder God Vime (Trypterigium wilfordii Hook F) with promising anticancer activity.However, their clinical application was limited by toxicity.We aim to investigate the synergistic anti-proliferative effects of triptolide with celastrol in cancer and the molecular mechanism.Methods: The effects of triptolide and celastrol on cancer cells and the molecular mechanism were assessed by using MTT assay in vitro, xenografts mouse model in vivo, flow cytometry, fluorescence microscope and western blot analysis.Results: The combination of triptolide with celastrol induced strong cell growth inhibition, cell cycle arrest at G2/M phase and apoptosis with the increasing intracellular ROS accumulation in cancer cells.Pretreatment with ROS scavenger N-acetyl-L-cysteine totally blocked the apoptosis induced by triptolide with celastrol.Treatment with celastrol alone decreased many Hsp90 client proteins including Akt,Cdks, EGFR and Raf1, but lead to stress-induced increase of Hsp70 and Hsp27.Adding triptolide to celastrol treatment abrogated this phenomenon and induced more apoptosis.In xenografts mouse model, the lower-dose combination of triptolide with celastrol significant inhibited the growth of tumors without obvious toxicity.Conclusions: Triptolide in combination with celastrol showed outstanding synergistic anticancer effect, suggesting that this beneficial combination may offer a promising treatment option for cancer patients.
其他文献
Objective: Linsitinib, a novel dual insulin-like growth factor 1 (IGF-1R)/insulin receptor (IR) kinase inhibitor in phase Ⅲ clinical trial, was investigated the reversal of multidrug resistance (MDR)
Background: Multidrug resistance (MDR) is a major impediment to the overall success of chemotherapy in clinical oncology.Recently, the intercellular transfer of ABCB1 between tumor cells has been prop
Objective: Largely due to the fact that most of patients suffering from ESCC are diagnosed at advanced states, the 5-year survival rate is merely 19%, which is the fourth worst among all cancers.Thus,
Cancer stem-like cells (CSC) have garnered significant attention as a therapeutic focus, based on evidence they may represent an etiologic root of treatment-resistant cells.Indeed, expression of the m
Lapatinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).Lapatinib can modulate the function of A
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths.Patient derived xenografts (PDX),generated by direct engraftment of tumor
会议
Objective: To explore the role of epithelial-mesenchymal transition(EMT) in the acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung ca
Objective: The cyclin-dependent kinase inhibitor 1A (CDKN1A), p21/Cipl, is a vital cell cycle regulator, dysregulation of which has been associated with a large number of human malignancies.One critic
会议
Objective: Ovarian cancer is one of the most lethal of woman cancers, and its clinical therapeutic effect is unsatisfied currently.Dinaciclib, a novel small molecule multi-CDKs inhibitor of CDK1/2/5/9
会议